Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.
Infusion of somatostatin, an inhibitor of glucagon secretion, in insulin-dependent diabetics resulted in a 75-100% reduction in the blood-glucose rise after oral glucose administration, but did not improve intravenous glucose tolerance. Somatostatin reduced blood-xylose levels by 50-90% after ingestion of this pentose and delayed the peak increment in blood-xylose by 1-2 h. Similar effects on blood-xylose levels and a 30% reduction in splanchnic blood-flow were observed in normal subjects during infusion of somatostatin. Glucagon administration (3 ng per kg per min) or intraduodenal administration of xylose did not reverse somatostatin's effect on xylose tolerance. Somatostatin reduces postprandial hyperglycaemia in diabetes primarily by decreasing and/or delaying carbohydrate absorption rather than enhancing carbohydrate disposal. This effect may be mediated, in part, but a reduction in splanchnic blood-flow. These findings indicate that postprandial hyperglycaemia in diabetes is due primarily to insulin deficiency rather than glucagon excess.
D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D050260:Carbohydrate Metabolism; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D004341:Drug Evaluation; D005934:Glucagon / Q000037:antagonists & inhibitors / Q000097:blood; D005947:Glucose / Q000008:administration & dosage; D005951:Glucose Tolerance Test; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000209:etiology*; D007275:Injections, Intravenous; D007328:Insulin / Q000172:deficiency; D007408:Intestinal Absorption / Q000187:drug effects*; D008875:Middle Aged; D013004:Somatostatin / Q000494:pharmacology* / Q000627:therapeutic use; D014994:Xylose / Q000008:administration & dosage / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D005934:Glucagon; D014994:Xylose; D005947:Glucose